OptiBiotix Health (LSE:OPTI) delivered solid performance in 2025, with revenue increasing 30% to £1.13 million. Gross profit rose 82% to £603,000, lifting margins to 53%, while operating costs remained broadly stable. The company ended the year with £1.03 million in cash and held investments in ProBiotix Health and SkinBioTherapeutics valued at £6.45 million. Product activity also gained momentum, highlighted by the launch of SlimBiome within the Hydroxycut brand and expanding customer engagement across Asian markets.
After the reporting period, OptiBiotix secured a 24-metric-tonne SlimBiome order from Taiwan-based Meelung Trading and recorded more than £800,000 in orders during January 2026, representing the strongest start to a year for the business. Management is now implementing a strategy focused on improving commercial sustainability, which includes reducing marketing and research-related spending, improving manufacturing economics for SlimBiome and introducing stricter profit-and-loss accountability across regional and distribution channels. The company aims to reach profitability across all business segments by the end of 2026.
Despite strong revenue momentum in 2024 and improving margins, the company’s outlook remains constrained by ongoing losses and continued cash burn. Technical indicators also show a prolonged downward trend with negative price momentum. However, OptiBiotix benefits from a debt-free balance sheet, which offers some financial stability, although valuation metrics remain difficult to support given negative earnings and the absence of a dividend yield.
More about OptiBiotix Health
OptiBiotix Health is a UK-listed life sciences company specialising in microbiome-based technologies designed to help prevent and manage human disease. The group develops and commercialises functional ingredients including SlimBiome, WellBiome, SweetBiotix and Microbiome Modulators. It also has exposure to probiotics and skincare through shareholdings in ProBiotix Health and SkinBioTherapeutics, targeting global markets in weight management, gut health and metabolic wellness.
The company supplies ingredients and finished products through international manufacturing, distribution and e-commerce channels, serving consumer health markets where demand for scientifically supported microbiome solutions and healthier sugar alternatives continues to grow.
Leave a Reply